Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiromu Horitani

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
BJUI Compass|May 1, 2026
Bone scan index rise prior to osteonecrosis of the jaw with bone-modifying agents in prostate cancerMasaru Tani, Koji Hatano, Takashi Kamiya, et al.
Scientific Reports|July 6, 2026
Peripheral B-cell receptor repertoire predicts immune-related adverse events following immune checkpoint inhibitor therapy in advanced renal cell carcinomaAkihiro Yoshimura, Taigo Kato, Yasutomo Nakai, et al.
Scientific Reports|December 12, 2025
Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective studyTaigo Kato, Yasutomo Nakai, Mototaka Sato, et al.
Cancer Treatment and Research Communications|May 29, 2026
Neutrophil-to-lymphocyte ratio and performance status are associated with increased risk of skin toxicity in patients receiving enfortumab vedotin with or without pembrolizumab for metastatic urothelial carcinomaYujiro Hayashi, Atsunari Kawashima, Yoshiyuki Yamamoto, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
BJUI Compass|May 1, 2026
Bone scan index rise prior to osteonecrosis of the jaw with bone-modifying agents in prostate cancerMasaru Tani, Koji Hatano, Takashi Kamiya, et al.
Scientific Reports|July 6, 2026
Peripheral B-cell receptor repertoire predicts immune-related adverse events following immune checkpoint inhibitor therapy in advanced renal cell carcinomaAkihiro Yoshimura, Taigo Kato, Yasutomo Nakai, et al.
Scientific Reports|December 12, 2025
Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective studyTaigo Kato, Yasutomo Nakai, Mototaka Sato, et al.
Cancer Treatment and Research Communications|May 29, 2026
Neutrophil-to-lymphocyte ratio and performance status are associated with increased risk of skin toxicity in patients receiving enfortumab vedotin with or without pembrolizumab for metastatic urothelial carcinomaYujiro Hayashi, Atsunari Kawashima, Yoshiyuki Yamamoto, et al.
Pageof 2